Patients are often non-adherent to topical corticosteroids (TCS). This may be in part due to poor communication between patients and dermatologists.
Objectives
This quality improvement (QI) study aims to describe dermatologist–patient communication about TCS treatments and to compare communication before and after the implementation of an educational intervention.
Methods
This QI study assesses the communication between dermatologists and new dermatology outpatients receiving a TCS prescription in a tertiary care center. The QI intervention is 2-pronged, consisting of an educational pamphlet for patients and a communication workshop for the dermatology team. Encounters were audiotaped, and communication was analyzed using a coding system (MEDICODE). Phase 1 recordings happened preintervention and reflect the usual dermatologist–patient communication in this practice setting and phase 2 recordings were postintervention.
Results
Phase 1 reveals that dermatologists frequently address informational medication themes, such as naming the medications and informing patients about their proper use. They less frequently discuss patient experience themes, such as goals of treatment, adverse effects of treatments, and exploring patients’ emotions about medications (such as anxiety, fears, etc.). After the intervention, there was more frequent discussion of patient experience themes without increasing consultation length. But, in both phases, physicians address most themes as a monolog with little verbal input from patients.
Conclusions
Our study raises awareness regarding dermatologists’ communication patterns about TCS, identifying specific areas for improvement, such as discussions of adverse effects, and explicitly addressing patients’ attitudes and emotions. This is an essential step to foster a sense-making of TCS for patients.
Get full access to this article
View all access options for this article.
References
1.
HixE.GustafsonCJ.O'NeillJLet al. Adherence to a five day treatment course of topical fluocinonide 0.1% cream in atopic dermatitis. Dermatol Online J. 2013;19(10):20029.
2.
StormA.BenfeldtE.AndersenSE.SerupJ. A prospective study of patient adherence to topical treatments: 95% of patients underdose. J Am Acad Dermatol. 2008;59(6):975-980.doi:10.1016/j.jaad.2008.07.039
3.
AliniaH.Moradi TuchayiS.SmithJAet al. Long-Term adherence to topical psoriasis treatment can be abysmal: a 1-year randomized intervention study using objective electronic adherence monitoring. Br J Dermatol. 2017;176(3):759-764.doi:10.1111/bjd.15085
4.
BrownKK.RehmusWE.KimballAB. Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol. 2006;55(4):607-613.doi:10.1016/j.jaad.2005.12.021
5.
FeldmanSR. Approaching psoriasis differently: patient-physician relationships, patient education and choosing the right topical vehicle. J Drugs Dermatol. 2010;9(8):908-911.
6.
ReichK.MrowietzU.KarakasiliE.ZschockeI. Development of an adherence-enhancing intervention in topical treatment termed the topical treatment optimization program (TTOP). Arch Dermatol Res. 2014;306(7):667-676.doi:10.1007/s00403-014-1475-5
7.
MüllerSM.TomaschettD.EulerS.VogtDR.HerzogL.ItinP. Topical corticosteroid concerns in dermatological outpatients: a cross-sectional and interventional study. Dermatology. 2016;232(4):444-452.doi:10.1159/000446068
8.
LiAW.YinES.AntayaRJ. Topical corticosteroid phobia in atopic dermatitis: a systematic review. JAMA Dermatol. 2017;153(10):1036-1042.doi:10.1001/jamadermatol.2017.2437
9.
El HachemM.GesualdoF.RicciGet al. Topical corticosteroid phobia in parents of pediatric patients with atopic dermatitis: a multicentre survey. Ital J Pediatr. 2017;43(1):22.doi:10.1186/s13052-017-0330-7
10.
Aubert-WastiauxH.MoretL.Le RhunAet al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br J Dermatol. 2011;165(4):808-814.doi:10.1111/j.1365-2133.2011.10449.x
TeasdaleEJ.MullerI.SanterM. Carers' views of topical corticosteroid use in childhood eczema: a qualitative study of online discussion forums. Br J Dermatol. 2017;176(6):1500-1507.doi:10.1111/bjd.15130
13.
BeattiePE.Lewis-JonesMS. Parental knowledge of topical therapies in the treatment of childhood atopic dermatitis. Clin Exp Dermatol. 2003;28(5):549-553.doi:10.1046/j.1365-2230.2003.01357.x
14.
AubertH.BarbarotS. Non adherence and topical steroids. Ann Dermatol Venereol. 2012;139(Suppl 1):S7-S12.doi:10.1016/S0151-9638(12)70102-3
15.
SmithSD.FarrugiaLL.HarrisVet al. Evaluation of the influence of family and friends, and the Internet on patient perceptions of long-term topical corticosteroid use. J Dermatolog Treat. 2017;28(7):642-646.doi:10.1080/09546634.2017.1306017
16.
FarrugiaLL.LeeA.FischerG.BlaszczynskiA.CarterSR.SmithSD. Evaluation of the influence of pharmacists and GPs on patient perceptions of long-term topical corticosteroid use. J Dermatolog Treat. 2017;28(2):112-118.doi:10.1080/09546634.2016.1213353
17.
MuellerSM.TomaschettD.VogtDRet al. Topical corticosteroid concerns from the clinicians' perspective. J Dermatolog Treat. 2017;28(5):464-468.doi:10.1080/09546634.2016.1255307
18.
SmithSD.HarrisV.LeeA.BlaszczynskiA.FischerG. General practitioners knowledge about use of topical corticosteroids in paediatric atopic dermatitis in Australia. Aust Fam Physician. 2017;46(5):335-340.
19.
GoffSL.MazorKM.MeterkoV.DoddK.SabinJ. Patients' beliefs and preferences regarding doctors' medication recommendations. J Gen Intern Med. 2008;23(3):236-241.doi:10.1007/s11606-007-0470-3
20.
JenkinsL.BrittenN.StevensonF.BarberN.BradleyC. Developing and using quantitative instruments for measuring doctor-patient communication about drugs. Patient Educ Couns. 2003;50(3):273-278.doi:10.1016/S0738-3991(03)00049-1
21.
BelcherVN.FriedTR.AgostiniJV.TinettiME. Views of older adults on patient participation in medication-related decision making. J Gen Intern Med. 2006;21(4):298-303.doi:10.1111/j.1525-1497.2006.00329.x
22.
LorimerS.CoxA.LangfordNJ. A patient's perspective: the impact of adverse drug reactions on patients and their views on reporting. J Clin Pharm Ther. 2012;37(2):148-152.doi:10.1111/j.1365-2710.2011.01258.x
23.
HudonC.St-Cyr TribbleD.BravoG.HoggW.LambertM.PoitrasM-E. Family physician enabling attitudes: a qualitative study of patient perceptions. BMC Fam Pract. 2013;14(1):8.doi:10.1186/1471-2296-14-8
24.
ZieglerDK.MosierMC.BuenaverM.OkuyemiK. How much information about adverse effects of medication do patients want from physicians?Arch Intern Med. 2001;161(5):706-713.doi:10.1001/archinte.161.5.706
25.
DickinsonD.RaynorDKT. What information do patients need about medicines? Ask the patients--they may want to know more than you think. BMJ. 2003;327(7419):861.doi:10.1136/bmj.327.7419.861-a
26.
BraddockCH.FihnSD.LevinsonW.JonsenAR.PearlmanRA. How doctors and patients discuss routine clinical decisions. Informed decision making in the outpatient setting. J Gen Intern Med. 1997;12(6):339-345.doi:10.1046/j.1525-1497.1997.00057.x
27.
ElwynG.EdwardsA.BrittenN. "Doing prescribing": how might clinicians work differently for better, safer care. Qual Saf Health Care. 2003;12(Suupl 1):i33-i36.doi:10.1136/qhc.12.suppl_1.i33
28.
CoxAR.ButtTF. Adverse drug reactions: when the risk becomes a reality for patients. Drug Saf. 2012;35(11):977-981.doi:10.2165/11636140-000000000-00000
29.
HugtenburgJG.BlomATG.KisoensinghSU. Initial phase of chronic medication use; patients' reasons for discontinuation. Br J Clin Pharmacol. 2006;61(3):352-354.doi:10.1111/j.1365-2125.2005.02569.x
30.
CareyN.StennerK.CourtenayM. Prescription writing for patients with diabetes: compliance with good practice. Igarss 2014. 2014;1:1-5.
31.
AgyapongVIO.NwankwoV.BangaruR.KirraneR. Sources of patients' knowledge of the adverse effects of psychotropic medication and the perceived influence of adverse effects on compliance among service users attending community mental health services. J Clin Psychopharmacol. 2009;29(6):565-570.doi:10.1097/JCP.0b013e3181befa3e
32.
PolinskiJM.KesselheimAS.FrolkisJP.WescottP.Allen-ColemanC.FischerMA. A matter of trust: patient barriers to primary medication adherence. Health Educ Res. 2014;29(5):755-763.doi:10.1093/her/cyu023
33.
TarnDM.PaternitiDA.WilliamsBR.CipriCS.WengerNS. Which providers should communicate which critical information about a new medication? patient, pharmacist, and physician perspectives. J Am Geriatr Soc. 2009;57(3):462-469.doi:10.1111/j.1532-5415.2008.02133.x
34.
ParrottR. Exploring family practitioners' and patients' information exchange about prescribed medications: implications for practitioners' interviewing and patients' understanding. Health Commun. 1994;6(4):267-280.doi:10.1207/s15327027hc0604_3
35.
RichardC.LussierM. The art of medical information exchange. Oxford Handb Heal Commun Behav Chang Treat Adherence. 2013:54-83.
36.
LussierM-T.RichardC.GlaserE.RobergeD. The impact of a primary care e-communication intervention on the participation of chronic disease patients who had not reached guideline suggested treatment goals. Patient Educ Couns. 2016;99(4):530-541.doi:10.1016/j.pec.2015.11.007
37.
BasakPY.OzturkM.BaysalV. Assessment of information and education about topical corticosteroids in dermatology outpatient departments: experience from Turkey. J Eur Acad Dermatology Venereol. 2003;17(6):652-658.doi:10.1046/j.1468-3083.2003.00723.x
38.
RichardC.LussierM-T. Nature and frequency of exchanges on medications during primary care encounters. Patient Educ Couns. 2006;64(1-3):207-216.doi:10.1016/j.pec.2006.02.003
39.
BajcarJ. Task analysis of patients' medication-taking practice and the role of making sense: a grounded theory study. Res Social Adm Pharm. 2006;2(1):59-82.doi:10.1016/j.sapharm.2005.12.005
40.
ReichK.ZschockeI.BachelezHet al. A topical treatment optimization programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP)*. Br J Dermatol. 2017;177(1):197-205.doi:10.1111/bjd.15466
41.
CorkMJ.BrittonJ.ButlerL.YoungS.MurphyR.KeohaneSG. Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse. Br J Dermatol. 2003;149(3):582-589.doi:10.1046/j.1365-2133.2003.05595.x
42.
ZuberbierT.OrlowSJ.PallerASet al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol. 2006;118(1):226-232.doi:10.1016/j.jaci.2006.02.031
43.
SafranDG.KosinskiM.TarlovARet al. The primary care assessment survey: tests of data quality and measurement performance. Med Care. 1998;36(5):728-739.doi:10.1097/00005650-199805000-00012
44.
RichardC.LussierM-T. MEDICODE: an instrument to describe and evaluate exchanges on medications that occur during medical encounters. Patient Educ Couns. 2006;64(1-3):197-206.doi:10.1016/j.pec.2006.02.002
45.
LussierM-T.RichardC. The motivational interview. Can Fam Physician. 2007;53(11):1895-1896.
46.
RichardC.GlaserE.LussierM-T. Communication and patient participation influencing patient recall of treatment discussions. Health Expect. 2017;20(4):760-770.doi:10.1111/hex.12515
47.
RoterDL.StewartM.PutnamSM.LipkinM.StilesW.InuiTS. Communication patterns of primary care physicians. JAMA. 1997;277(4):350-356.doi:10.1001/jama.1997.03540280088045
48.
TarnDM.PaternitiDA.KravitzRLet al. How much time does it take to prescribe a new medication?Patient Educ Couns. 2008;72(2):311-319.doi:10.1016/j.pec.2008.02.019
49.
AdamsK.CiminoJEW.ArnoldRM.AndersonWG. Why should I talk about emotion? Communication patterns associated with physician discussion of patient expressions of negative emotion in hospital admission encounters. Patient Educ Couns. 2012;89(1):44-50.doi:10.1016/j.pec.2012.04.005
50.
LinnAJ.van WeertJC.SchoutenBC.SmitEG.van BodegravenAA.van DijkL. Words that make pills easier to swallow: a communication typology to address practical and perceptual barriers to medication intake behavior. Patient Prefer Adherence. 2012;6:871-885.doi:10.2147/PPA.S36195
51.
RichardC.GlaserE.LussierM-T. Communication and patient participation influencing patient recall of treatment discussions. Health Expect. 2017;20(4):760-770.doi:10.1111/hex.12515
52.
SibleyA.LatterS.RichardCet al. Medication discussion between nurse prescribers and people with diabetes: an analysis of content and participation using MEDICODE. J Adv Nurs. 2011;67(11):2323-2336.doi:10.1111/j.1365-2648.2011.05686.x
53.
NguyenTV.HongJ.ProseNS. Compassionate care: enhancing physician-patient communication and education in dermatology: Part I: patient-centered communication. J Am Acad Dermatol. 2013;68(3):353.e1-8.doi:10.1016/j.jaad.2012.10.059
54.
StevensonFA.CoxK.BrittenN.DundarY. A systematic review of the research on communication between patients and health care professionals about medicines: the consequences for concordance. Heal Expect. 2004;7(3):235-245.doi:10.1111/j.1369-7625.2004.00281.x
55.
CollierR. Reducing the "pill burden". Can Med Assoc J. 2012;184(2):E117-E118.doi:10.1503/cmaj.109-4076
56.
ZolnierekKBH.DimatteoMR. Physician communication and patient adherence to treatment: a meta-analysis. Med Care. 2009;47(8):826-834.doi:10.1097/MLR.0b013e31819a5acc
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
